BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs 
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is...
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million...
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit H.E. Dr. Majid...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical...
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by...
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in...
LUKE Calls for National Partnerships to Help America’s Heroes Flourish
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville...
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies...
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of...
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading...
CARBIOS presents its 2025 half-year results and confirms its objective to build a PET biorecycling plant, with a revised timeline.
CARBIOS has reduced its operating expenses and has a strong cash position of €72 million as of June...
Burning Rock’s OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech...
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in...
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety...
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund...